Journal asmac No 3 - juin 2021

Perspectives
Referenzen (Fortsetzung)
27. Smith MR: Rituximab
(monoclonal anti-CD20 antibody):
mechanisms of action and
resistance. Oncogene 2003; 22:
7359–7368.
28. Coiffier B, Lepage E,
Briere J, et al.: CHOP chemotherapy
plus rituximab compared with
CHOP alone in elderly patients
with diffuse large-B-cell lymphoma.
N Engl J Med 2002; 346:
235–242.
29. Diehl V, Sextro M,
Franklin J, et al.: Clinical
presentation, course, and
prognostic factors in lymphocyte-predominant
Hodgkin’s
disease and lymphocyte-rich
classical Hodgkin’s disease: report
from the European Task Force on
Lymphoma Project on Lymphocyte-Predominant
Hodgkin’s
Disease. J Clin Oncol 1999; 17:
776–783.
30. Morschhauser F,
Marlton P, Vitolo U, et al.: Results
of a phase I/II study of ocrelizumab,
a fully humanized
anti-CD20 mAb, in patients with
relapsed/refractory follicular
lymphoma. Ann Oncol 2010; 21:
1870–1876.
31. Umaña P, Jean-Mairet J,
Moudry R, Amstutz H, Bailey JE:
Engineered glycoforms of an
antineuroblastoma IgG1 with
optimized antibody-dependent
cellular cytotoxic activity. Nat
Biotechnol 1999; 17: 176–180.
32. Lozanski G, Heerema
NA, Flinn IW, et al.: Alemtuzumab
is an effective therapy for chronic
lymphocytic leukemia with p53
mutations and deletions. Blood
2004; 103: 3278–3281.
33. Usmani SZ, Weiss BM,
Plesner T, et al.: Clinical efficacy of
daratumumab monotherapy in
patients with heavily pretreated
relapsed or refractory multiple
myeloma. Blood 2016; 128: 37–44.
34. Gopal AK, Ramchandren
R, O’Connor OA, et al.: Safety
and efficacy of brentuximab
vedotin for Hodgkin lymphoma
recurring after allogeneic stem cell
transplantation. Blood 2012; 120:
560–568.
35. Sutherland MS,
Sanderson RJ, Gordon KA, et al.:
Lysosomal trafficking and cysteine
protease metabolism confer
target-specific cytotoxicity by
peptide-linked anti-CD30-auristatin
conjugates. J Biol Chem 2006;
281: 10540–10547.
36. Kantarjian H, Stein A,
Gökbuget N, et al.: Blinatumomab
versus chemotherapy for advanced
acute lymphoblastic leukemia.
N Engl J Med 2017; 376: 836–847.
37. Lee DW, Gardner R,
Porter DL, et al.: Current concepts
in the diagnosis and management
of cytokine release syndrome.
Blood 2014; 124: 188–195.
38. Teachey DT, Rheingold
SR, Maude SL, et al.: Cytokine
release syndrome after blinatumomab
treatment related to abnormal
macrophage activation and ameliorated
with cytokine-directed
therapy. Blood 2013; 121: 5154–5157.
39. Garrido F, Aptsiauri N,
Doorduijn EM, Garcia Lora AM,
van Hall T: The urgent need to
recover MHC class I in cancers for
effective immunotherapy. Curr
Opin Immunol 2016; 39: 44–51.
40. Dai H, Wang Y, Lu X,
Han W: Chimeric antigen receptors
modified t-cells for cancer therapy.
J Natl Cancer Inst 2016; 108: pii:
djv439.
41. Zhang C, Liu J, Zhong
JF, Zhang X: Engineering CAR-T
cells. Biomark Res 2017; 5: 22.
42. Maude SL, Frey N, Shaw
PA,et al.: Chimeric antigen
receptor T cells for sustained
remissions in leukemia. N Engl J
Med 2014; 371: 1507–1517.
43. Turtle CJ, Hanafi LA,
Berger C, et al.: CD19 CAR-T cells of
defined CD4+:CD8+ composition in
adult B cell ALL patients. J Clin
Invest 2016; 126: 2123–2138.
44. Lee DW, Kochenderfer
JN, Stetler-Stevenson M, et al.: T
cells expressing CD19 chimeric
antigen receptors for acute
lympho blastic leukaemia in
children and young adults: a phase
1 dose-escalation trial. Lancet 2015;
385: 517–528.
45. Ritchie DS, Neeson PJ,
Khot A, et al.: Persistence and
efficacy of second generation CAR
T cell against the LeY antigen in
acute myeloid leukemia. Mol Ther
2013; 21: 2122–2129.
46. Levine BL: Performance-enhancing
drugs: design
and production of redirected
chimeric antigen receptor (CAR) T
cells. Cancer Gene Ther 2015; 22:
79–84.
47. Garfall AL, Maus MV,
Hwang WT, et al.: Chimeric antigen
receptor T cells against CD19 for
multiple myeloma. N Engl J Med
2015; 373: 1040–1047.
48. Kochenderfer JN,
Dudley ME, Kassim SH, et al.:
Chemotherapy-refractory diffuse
large B-cell lymphoma and
indolent B-cell malignancies can
be effectively treated with
autologous T cells expressing an
anti-CD19 chimeric antigen
receptor. J Clin Oncol 2015; 33:
540–549.
49. Neelapu SS, Locke FL,
Bartlett NL, et al.: Axicabtagene
cilo leucel CAR T-cell therapy in
refractory large B-cell lymphoma.
N Engl J Med 2017; 377: 2531–2544.
50. Brudno JN, Somerville
RP, Shi V, et al.: Allogeneic T cells
that express an anti-CD19 chimeric
antigen receptor induce remissions
of B-cell malignancies thatprogress
after allogeneic hematopoietic
stem-cell transplantation without
causing graft-versus-host disease.
J Clin Oncol 2016; 34: 1112–1121.
51. Gauthier J, Turtle CJ:
Insights into cytokine release
syndrome and neurotoxicity after
CD19-specific CAR-T cell therapy.
Curr Res Transl Med 2018; 66:
50–52.
52. Dong H, Somerville RP,
Shi V, et al.: Tumor-associated
B7-H1 promotes T-cell apoptosis: a
potential mechanism of immune
evasion. Nat Med 2002; 8: 793–800.
53. Walunas TL, Lenschow
DJ, Bakker CY, et al.: CTLA-4 can
function as a negative regulator of
T cell activation. Immunity 1994; 1:
405–413.
54. Green MR, Monti S,
Rodig SJ, et al.: Integrative analysis
reveals selective 9p24.1 amplification,
increased PD-1 ligand
expression, and further induction
via JAK2 in nodular sclerosing
Hodgkin lymphoma and primary
mediastinal large B-cell
lymphoma. Blood 2010; 116:
3268–3277.
55. Twa DD, Chan FC,
Ben-Neriah S, et al.: Genomic
rearrangements involving
programmed death ligands are
recurrent in primary mediastinal
large B-cell lymphoma. Blood 2014;
123: 2062–2065.
56. Pardoll DM: The
blockade of immune checkpoints
in cancer immunotherapy. Nat Rev
Cancer 2012; 12: 252–264.
57. Ansell SM, Lesokhin
AM, Borrello I, et al.: PD-1 blockade
with nivolumab in relapsed or
refractory Hodgkin’s lymphoma.
N Engl J Med 2015; 372: 311–319.
58. Armand P, Shipp MA,
Ribrag, et al.: Programmed death-1
blockade with pembrolizumab in
patients with classical hodgkin
lymphoma after brentuximab
vedotin failure. J Clin Oncol 2016;
34: 3733–3739.
59. Chen R, Zinzani PL,
Fanale MA, et al.: Phase II study of
the efficacy and safety of
pembrolizumab for relapsed/
refractory classic Hodgkin
lymphoma. J Clin Oncol 2017:
35:2125–2132.
60. Lesokhin AM, Ansell
SM, Armand P, et al.: Nivolumab in
patients with relapsed or refractory
hematologic malignancy:
Preliminary results of a phase Ib
study. J Clin Oncol 2016; 34:
2698–2704.
61. Hude I, Sasse S, Engert
A, Bröckelmann PJ: The emerging
role of immune checkpoint
inhibition in malignant lymphoma.
Haematologica 2017; 102:
30–42.
62. Ansell SM, Hurvitz SA,
Koenig PA, et al.: Phase I study of
ipilimumab, an anti-CTLA-4
monoclonal antibody, in patients
with relapsed and refractory B-cell
non-Hodgkin lymphoma. Clin
Cancer Res 2009; 15: 6446–6453.
63. Nastoupil LJ. Westin J,
Fowler N, et al.: High response
rates with pembrolizumab in
combination with rituximab in
patients with relapsed follicular
lymphoma: interim results of an on
open-label, phase II study. J Clin
Oncol 2017; 35: abstr 7519.
46
3/21 vsao /asmac Journal